{"id":758193,"date":"2023-05-11T18:21:13","date_gmt":"2023-05-11T22:21:13","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/viracta-therapeutics-to-present-at-the-rbc-capital-markets-global-healthcare-conference\/"},"modified":"2023-05-11T18:21:13","modified_gmt":"2023-05-11T22:21:13","slug":"viracta-therapeutics-to-present-at-the-rbc-capital-markets-global-healthcare-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/viracta-therapeutics-to-present-at-the-rbc-capital-markets-global-healthcare-conference\/","title":{"rendered":"Viracta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">SAN DIEGO, May  11, 2023  (GLOBE NEWSWIRE) &#8212; Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced that Mark Rothera, its President and Chief Executive Officer, and Dan Chevallard, its Chief Operating Officer and Chief Financial Officer, are scheduled to participate in a fireside chat at the RBC Capital Markets Global Healthcare Conference on Wednesday, May 17, 2023, at 4:05 p.m. EDT.<\/p>\n<p align=\"justify\">A live webcast of the fireside chat will be available on the Investors section of the Viracta website under &#8220;<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=EEKhF31ySzjDTaHq91ngvBEIBjz99nUXlgdb7hDszbr1EqRP37bnCQtJ62gJuSTz8-5SXbWaymwHxOR4SBX9ArS-8GCym9JljS0HzNGdofzYCqdsf8gLQ4LSsnYmFBXw\" rel=\"nofollow noopener\" target=\"_blank\">Events and Webcasts<\/a>&#8221; and archived for 90 days.<\/p>\n<p align=\"justify\">\n        <strong>About Viracta Therapeutics, Inc.<\/strong>\n      <\/p>\n<p align=\"justify\">Viracta is a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide. Viracta\u2019s lead product candidate is an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir (collectively referred to as Nana-val). Nana-val is currently being evaluated in multiple ongoing clinical trials, including a pivotal, global, multicenter, open-label Phase 2 basket trial for the treatment of multiple subtypes of relapsed\/refractory Epstein-Barr virus-positive (EBV<sup>+<\/sup>) lymphoma (NAVAL-1), as well as a multinational, open-label Phase 1b\/2 trial for the treatment of EBV<sup>+<\/sup>\u00a0recurrent or metastatic nasopharyngeal carcinoma and other advanced EBV<sup>+<\/sup>\u00a0solid tumors. Viracta is also pursuing the application of its \u201c<em>Kick and Kill\u201d<\/em>\u00a0approach in other virus-related cancers.<\/p>\n<p align=\"justify\">For additional information please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=zBMHY_3AGq0-_8P04-n5HQy4txZUkqmx7ukWNJ187YKvTTjB27IAv4CvK6CeIN4Zie8xsEkxX06O4GzRq5SS4g==\" rel=\"nofollow noopener\" target=\"_blank\">www.viracta.com<\/a>.<\/p>\n<p>\n        <strong>Investor Relations Contact:<\/strong><br \/>\n        <br \/>Ashleigh Barreto<br \/>Head of Investor Relations &amp; Corporate Communications<br \/>Viracta Therapeutics, Inc.<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=zVQW-mMBX9_m8KjjoqciBYlkgcNdrXedcz35XGEUAJMo_H80pCuG2j_sfzwAgxtxtWl9k5dLN4NN7s9w7GmwxLfu0U4zZFRwEW9ZtqfG4u4=\" rel=\"nofollow noopener\" target=\"_blank\">abarreto@viracta.com<\/a><\/p>\n<p>SOURCE Viracta Therapeutics, Inc.<\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzNzcxMCM1NTkwOTY0IzUwMDEwOTIxNw==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/NjMxYjg3NDktMTc4YS00NDg2LTk0N2UtYzdlNDEwY2Y5YWU5LTUwMDEwOTIxNw==\/tiny\/Viracta-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SAN DIEGO, May 11, 2023 (GLOBE NEWSWIRE) &#8212; Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced that Mark Rothera, its President and Chief Executive Officer, and Dan Chevallard, its Chief Operating Officer and Chief Financial Officer, are scheduled to participate in a fireside chat at the RBC Capital Markets Global Healthcare Conference on Wednesday, May 17, 2023, at 4:05 p.m. EDT. A live webcast of the fireside chat will be available on the Investors section of the Viracta website under &#8220;Events and Webcasts&#8221; and archived for 90 days. About Viracta Therapeutics, Inc. Viracta is a precision oncology company focused on the treatment and prevention &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/viracta-therapeutics-to-present-at-the-rbc-capital-markets-global-healthcare-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Viracta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-758193","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Viracta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/viracta-therapeutics-to-present-at-the-rbc-capital-markets-global-healthcare-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Viracta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SAN DIEGO, May 11, 2023 (GLOBE NEWSWIRE) &#8212; Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced that Mark Rothera, its President and Chief Executive Officer, and Dan Chevallard, its Chief Operating Officer and Chief Financial Officer, are scheduled to participate in a fireside chat at the RBC Capital Markets Global Healthcare Conference on Wednesday, May 17, 2023, at 4:05 p.m. EDT. A live webcast of the fireside chat will be available on the Investors section of the Viracta website under &#8220;Events and Webcasts&#8221; and archived for 90 days. About Viracta Therapeutics, Inc. Viracta is a precision oncology company focused on the treatment and prevention &hellip; Continue reading &quot;Viracta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/viracta-therapeutics-to-present-at-the-rbc-capital-markets-global-healthcare-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-05-11T22:21:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzNzcxMCM1NTkwOTY0IzUwMDEwOTIxNw==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/viracta-therapeutics-to-present-at-the-rbc-capital-markets-global-healthcare-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/viracta-therapeutics-to-present-at-the-rbc-capital-markets-global-healthcare-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Viracta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference\",\"datePublished\":\"2023-05-11T22:21:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/viracta-therapeutics-to-present-at-the-rbc-capital-markets-global-healthcare-conference\\\/\"},\"wordCount\":262,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/viracta-therapeutics-to-present-at-the-rbc-capital-markets-global-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgzNzcxMCM1NTkwOTY0IzUwMDEwOTIxNw==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/viracta-therapeutics-to-present-at-the-rbc-capital-markets-global-healthcare-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/viracta-therapeutics-to-present-at-the-rbc-capital-markets-global-healthcare-conference\\\/\",\"name\":\"Viracta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/viracta-therapeutics-to-present-at-the-rbc-capital-markets-global-healthcare-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/viracta-therapeutics-to-present-at-the-rbc-capital-markets-global-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgzNzcxMCM1NTkwOTY0IzUwMDEwOTIxNw==\",\"datePublished\":\"2023-05-11T22:21:13+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/viracta-therapeutics-to-present-at-the-rbc-capital-markets-global-healthcare-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/viracta-therapeutics-to-present-at-the-rbc-capital-markets-global-healthcare-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/viracta-therapeutics-to-present-at-the-rbc-capital-markets-global-healthcare-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgzNzcxMCM1NTkwOTY0IzUwMDEwOTIxNw==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgzNzcxMCM1NTkwOTY0IzUwMDEwOTIxNw==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/viracta-therapeutics-to-present-at-the-rbc-capital-markets-global-healthcare-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Viracta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Viracta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/viracta-therapeutics-to-present-at-the-rbc-capital-markets-global-healthcare-conference\/","og_locale":"en_US","og_type":"article","og_title":"Viracta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference - Market Newsdesk","og_description":"SAN DIEGO, May 11, 2023 (GLOBE NEWSWIRE) &#8212; Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced that Mark Rothera, its President and Chief Executive Officer, and Dan Chevallard, its Chief Operating Officer and Chief Financial Officer, are scheduled to participate in a fireside chat at the RBC Capital Markets Global Healthcare Conference on Wednesday, May 17, 2023, at 4:05 p.m. EDT. A live webcast of the fireside chat will be available on the Investors section of the Viracta website under &#8220;Events and Webcasts&#8221; and archived for 90 days. About Viracta Therapeutics, Inc. Viracta is a precision oncology company focused on the treatment and prevention &hellip; Continue reading \"Viracta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/viracta-therapeutics-to-present-at-the-rbc-capital-markets-global-healthcare-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2023-05-11T22:21:13+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzNzcxMCM1NTkwOTY0IzUwMDEwOTIxNw==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/viracta-therapeutics-to-present-at-the-rbc-capital-markets-global-healthcare-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/viracta-therapeutics-to-present-at-the-rbc-capital-markets-global-healthcare-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Viracta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference","datePublished":"2023-05-11T22:21:13+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/viracta-therapeutics-to-present-at-the-rbc-capital-markets-global-healthcare-conference\/"},"wordCount":262,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/viracta-therapeutics-to-present-at-the-rbc-capital-markets-global-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzNzcxMCM1NTkwOTY0IzUwMDEwOTIxNw==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/viracta-therapeutics-to-present-at-the-rbc-capital-markets-global-healthcare-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/viracta-therapeutics-to-present-at-the-rbc-capital-markets-global-healthcare-conference\/","name":"Viracta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/viracta-therapeutics-to-present-at-the-rbc-capital-markets-global-healthcare-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/viracta-therapeutics-to-present-at-the-rbc-capital-markets-global-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzNzcxMCM1NTkwOTY0IzUwMDEwOTIxNw==","datePublished":"2023-05-11T22:21:13+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/viracta-therapeutics-to-present-at-the-rbc-capital-markets-global-healthcare-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/viracta-therapeutics-to-present-at-the-rbc-capital-markets-global-healthcare-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/viracta-therapeutics-to-present-at-the-rbc-capital-markets-global-healthcare-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzNzcxMCM1NTkwOTY0IzUwMDEwOTIxNw==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzNzcxMCM1NTkwOTY0IzUwMDEwOTIxNw=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/viracta-therapeutics-to-present-at-the-rbc-capital-markets-global-healthcare-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Viracta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/758193","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=758193"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/758193\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=758193"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=758193"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=758193"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}